Germany: no added benefit for Teysuno in gastric cancer

Germany's Federal Joint Committee (G-BA) said in a preliminary benefit assessment that Teysuno tegafur/gimeracil/oteracil from Nordic Group (Paris, France) offers no additional benefit over Xeloda capecitabine or 5-fluorouracil (5-FU) as first-line treatment of advanced gastric cancer in combination with cisplatin. G-BA said in the assessment that Nordic did not submit necessary data despite requests by the committee. Nordic told BioCentury that Teysuno will continue to be marketed in Germany and that the drug would undergo the "standard pricing process." The company would not provide further details. ...